Rovi jumps after announcing drug deal with Roche

Laboratorios Farmaceuticos Rovi

21/10/2025 16:34

** Shares in Rovi ROVI.MC rise about 8% after the Spanish drugmaker announced a deal with a unit of Switzerland's Roche ROG.S

** Rovi is set to manufacture a new medicine from Roche's metabolic and cardiovascular portfolio

** Rovi estimates the deal will contribute to a minimum increase of 20% to 25% in contract manufacturing business sales compared with 2024

** "This is the agreement that we hoped Rovi would sign this year," Bestinver analyst Patricia Cifuentes says, adding the product could start contributing to sales by 2029, with a "significant" impact

** "We assume a robust EBITDA margin for Rovi and a 75% probability of success for this product, as Rovi will invest (and Roche will pay) to prepare the existing capacity," Cifuentes adds

** The initiative will have an estimated impact of 2 billion euros in direct and indirect benefits in Spain, managing director of Roche Farma in Spain Patrick Wallach says

** Shares are on track for their best day since July 2023

(Reporting by Javi West Larrañaga)

((javier.west@thomsonreuters.com; +34 918 35 61 12))